CX-4945An ATP-competitive CK2 protein kinase inhibitor

CX-4945 (CAS 1009820-21-6)

CX-4945 | CAS 1009820-21-6 is rated 5.0 out of 5 by 2.
  • y_2019, m_9, d_17, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_2
  • loc_en_US, sid_364475, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 116ms
  • REVIEWS, PRODUCT
Synonym: Silmitasertib
Application: An ATP-competitive CK2 protein kinase inhibitor
CAS Number: 1009820-21-6
Purity: ≥95%
Molecular Weight: 349.77
Molecular Formula: C19H12ClN3O2
* Refer to Certificate of Analysis for lot specific data (including water content).
submit a review for this product and receive 15 cruzcredits

CX-4945 (Silmitasertib) is an ATP-competitive CK2 protein kinase inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively. CX-4945 has broad-spectrum anti-proliferative activity in multiple cancer cell lines. The anti-proliferative activity of CX-4945 against cancer cells correlated with expression levels of the CK2α catalytic subunit. Attenuation of PI3K/Akt signaling by CX-4945 was evidenced by dephosphorylation of Akt on the CK2-specific S129 site and the canonical S473 and T308 regulatory sites. CX-4945 suppresses Akt signaling and inhibits proliferation of HUVEC Cells. CX-4945 causes cell-cycle arrest and selectively induced apoptosis in certain cancer cells. In models of angiogenesis, CX-4945 inhibited human umbilical vein endothelial cell migration, tube formation, and blocked CK2-dependent hypoxia-induced factor 1 alpha (HIF-1α) transcription in cancer cells. Collectively, CX-4945 inhibits pro-angiogenic CK2 signaling in vitro and in vivo. CX-4945 is an inhibitor of Flt-3/Flk-2 and Pim-1.

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in water (<1.2 mg/ml), DMSO (≥65 mg/ml), and ethanol (<1.2 mg/ml).
Storage :
Store at -20° C
Boiling Point :
~568.5 °C at 760 mmHg (Predicted)
Density :
~1.5 g/cm3 (Predicted)
Refractive Index :
n20D 1.79 (Predicted)
IC50 :
Casein kinase IIα: IC50 = 1 nM (human); ZIP-kinase: IC50 = 17 nM (human); TBK1: IC50 = 35 nM (human); CLK3: IC50 = 41 nM (human); HIPK3: IC50 = 45 nM (human)
pK Values :
pKa: 2.96 (Predicted), pKb: 4.04 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
24748573
MDL Number :
MFCD13184796
SMILES :
C1=CC(=CC(=C1)Cl)NC2=C3C=CN=CC3=C4C=CC(=CC4=N2)C(=O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

CX-4945  Product Citations

See how others have used CX-4945. Click on the entry to view the PubMed entry .

Citations 1 to 6 of 6 total

PMID: # 30600261  Pankow, S.|Bamberger, C.|Yates, JR.| et al. 2019. Sci Signal. 12:

PMID: # 30142881  Lertsuwan, J.|Lertsuwan, K.|Sawasdichai, A.|Tasnawijitwong, N.|Lee, KY.|Kitchen, P.|Afford, S.|Gaston, K.|Jayaraman, PS.|Satayavivad, J.| et al. 2018. Cancers (Basel). 10:

PMID: # 28223413  Viscarra, JA. et al. 2017. Sci Signal. 10:

PMID: # 28873435  Lustri, AM. et al. 2017. PLoS ONE. 12: e0183932.

PMID: # 27707883  de Bourayne, M.|Gallais, Y.|El Ali, Z.|Rousseau, P.|Damiens, MH.|Cochet, C.|Filhol, O.|Chollet-Martin, S.|Pallardy, M.|Kerdine-Römer, S.| et al. 2017. J. Leukoc. Biol. 101: 703-715.

PMID: # 27033073  Misticone, S. et al. 2016. Methods in molecular biology (Clifton, N.J.). 1388: 95-110.

Citations 1 to 6 of 6 total

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. CX-4945, sc-364475, is in orange powder form.
Answered by: Chemical Support 4
Date published: 2017-04-04
  • y_2019, m_9, d_17, h_8CST
  • bvseo_bulk, prod_bvqa, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_364475, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 97ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from worked good Dissolved well in DMSO and worked as expected.....
Date published: 2018-01-08
Rated 5 out of 5 by from Kim et al Kim et al. (PubMed ID 26318800) used CX-4945, a CK2 inhibitor, to block the FAK-Src-pacillin signaling pathway and TGF- -induced cancer cell metastasis. -SCBT Publication Review
Date published: 2015-02-10
  • y_2019, m_9, d_16, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_2
  • loc_en_US, sid_364475, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 39ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.